ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Guillermo Garcia-Manero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.